NGeneBio participated in WHX Labs Dubai 2026, held in Dubai from February 9 to 12.

At the event, the company operated an independent booth showcasing its next-generation NGS precision diagnostics software, NGeneAnalySys™ (NGAS), along with its enhanced version, NGeneAnalySys 2.0. The presentation highlighted seamless integration with hospital workflows and outlined the strategic roadmap for AI model implementation.

In addition, NGeneBio held strategic meetings with more than 70 local healthcare institutions and global pharmaceutical and biotech companies, sharing real-world clinical applications and demonstrating the scalability of its platform.

Following the successful conclusion of the exhibition, NGeneBio plans to further strengthen its data-driven precision medicine collaboration models. Leveraging its operational track record across 28 countries, the company aims to accelerate its phased expansion strategy in the Middle East and other global markets.